- Home
- BTE vs KNSA Comparison
BTE vs KNSA Comparison
Compare BTE & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
Current Price
$4.01
N/A
Current Price
$46.81
Company Overview
Basic Information| Metric | BTE | KNSA |
|---|---|---|
| Founded | 1993 | 2015 |
| Country | Canada | United Kingdom |
| Employees | N/A | N/A |
| Industry | Meat/Poultry/Fish | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 3.4B |
| IPO Year | 2004 | 2018 |
Fundamental Metrics
Financial Performance| Metric | BTE | KNSA |
|---|---|---|
| Price | $4.01 | $46.81 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $55.29 |
| AVG Volume (30 Days) | ★ 17.5M | 595.3K |
| Earning Date | 01-01-0001 | 05-18-2026 |
| Dividend Yield | ★ 1.64% | N/A |
| EPS Growth | N/A | ★ 225.00 |
| EPS | N/A | ★ 0.75 |
| Revenue | N/A | ★ $677,564,000.00 |
| Revenue This Year | N/A | $38.01 |
| Revenue Next Year | $35.09 | $17.42 |
| P/E Ratio | ★ $18.43 | $61.29 |
| Revenue Growth | N/A | ★ 60.09 |
| 52 Week Low | $1.36 | $18.26 |
| 52 Week High | $4.13 | $49.12 |
Technical Indicators
Market Signals| Indicator | BTE | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 68.32 | 57.86 |
| Support Level | $3.59 | $40.47 |
| Resistance Level | N/A | $49.12 |
| Average True Range (ATR) | 0.17 | 2.17 |
| MACD | 0.01 | 0.05 |
| Stochastic Oscillator | 77.57 | 71.13 |
Price Performance
Historical Comparison BTE
KNSA
About BTE Baytex Energy Corp
Baytex Energy Corp is an oil and gas company. Geographically, the group operates in Canada and the United States. The company derives a majority of revenue from Canada. Its Canada segment includes the exploration, development, and production of crude oil and natural gas in Western Canada.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.